ABSTRACT BACKGROUND Transcatheter aortic valve replacement (TAVR) enables treatment of high-risk patients with symptomatic
has been shown to be superior to standard medical therapy for inoperable patients and to be at least noninferior to SAVR in high-risk patients with severe symptomatic aortic stenosis (2) (3) (4) (5) .
The benefits associated with the application of TAVR, however, are mitigated by the potential of major, disabling stroke with associated increased mortality and early reduced quality of life (6) . Despite rapid adoption of this technology into clinical practice, reports from recent randomized controlled clinical trials have raised safety concerns regarding an increased risk of neurological events with TAVR compared to both medical treatment and conventional SAVR. In patients undergoing TAVR with the Sapien valve from the PARTNER (Placement of Aortic Transcatheter Valves) trials, 30-day rates of stroke or transient ischemic attack (TIA) of 6.7% for inoperable patients and 5.5% in patients deemed at high risk were reported (7, 8) . These same studies reported 30-day rates of stroke or TIA of 1.7% with medical management alone and 2.4% with SAVR. In the randomized CoreValve US Pivotal High Risk Trial, the rate of any stroke was numerically higher in the surgical group than in the TAVR group (6.2% vs. 4.9%) at 30 days (4) . However, for an already rapidly expanding treatment modality, data coming from carefully monitored, very large "real-world" patient cohorts are still relatively scarce and complementary to randomized trial data. The CoreValve ADVANCE Study was designed to evaluate clinical outcomes, including stroke and TIA, in real-life patients at experienced implanting centers (excluding possible "learning curve" influences). All adverse event adjudication occurred by an independent Clinical Events Committee according to the original definitions of the Valve Academic Research Consortium (VARC-1) (9) .
The aim of this specific analysis was to characterize the incidence, timing, type, and predictors of clinically relevant neurological events in "real-life" selfexpandable system TAVR patients out to 2 years after the procedure.
METHODS
The ADVANCE study methods, procedures, and a detailed description of the study device (CoreValve Transcatheter Aortic Valve, Medtronic, Inc., Minneapolis, Minnesota) have been previously described (5) . In brief, ADVANCE is a prospective, multicenter, fully monitored, nonrandomized study that included 44 sites in 12 countries in Europe, Israel, and Colombia. Each investigational site was required to have performed at least 40 TAVR procedures to be considered. A heart team, comprising at least 1 TAVRexperienced interventional cardiologist and 1 cardiothoracic surgeon, determined the surgical risk status and study eligibility of each patient.
The aim of the ADVANCE study was to evaluate clinical outcomes after treatment with a selfexpandable system in real-world practice. Therefore the exclusion criteria were limited to patients participating in another trial that would interfere with routine practice and patients who were unwilling or unable to provide written informed consent. Wenaweser has received consulting fees from Medtronic and Edwards Lifesciences; remuneration for study related travel and for developing education materials from Medtronic; and lecture and proctoring fees as well as travel support from Edwards Life event after TAVR was related to unique or competing causes by evaluating the incidence and predictors of stroke, and the composite of stroke and TIA, at 3 distinct time intervals: periprocedural (0 to 1 day post-TAVR); early (2 to 30 days); and late (31 to 730 days). We also evaluated the effect of stroke after TAVR on survival through 2 years.
The implanting physician chose the methods used to evaluate the size of the access vessels and aortic annulus. In this study, a self-expandable system was implanted via an 18-F delivery catheter, and 26 mm and 29 mm valve sizes were implanted to treat native In the selection process of potential predictors, we also excluded rare characteristics or events that occurred in #5% of the total risk set for a given time Stroke Outcomes From the ADVANCE Study performed using SAS version 9.3 software (SAS Institute Inc., Cary, North Carolina).
RESULTS
From March 2010 through July 2011, 1,015 patients were enrolled in the ADVANCE study, of whom 996 had an attempted implant with the self-expandable system. Mean age was 81.1 AE 6.4 years, 51% were female, 79.6% of patients had New York Heart Association functional class III or IV symptoms, and 13.1%
had cerebrovascular disease at baseline.
The overall rate of stroke was 1.4% through the first day post-procedure, 3.0% at 30 days, and 5.6% at 2 years; with major stroke rates of 0.5%, 1.2%, and 2.9% for the same time periods, respectively.
No statistically significant differences were found between the patients who developed a stroke or a stroke/TIA and patients who did not develop a periprocedural neurological event (all p >0.05). Online Tables 1 and 2 We also evaluated the effect of valve implant access route on stroke and stroke/TIA events in the early time period after TAVR. There were no significant differences in the rate of stroke or in the rate of stroke or TIA on the basis of access (Online Table 4 ).
Survival through 2 years for patients with and without a stroke, and for those with and without a stroke/TIA, within the first 30 days post-TAVR is shown in Figure 3 .
PREDICTORS OF STROKE OR STROKE/TIA. None of the univariable predictors examined (Online Table 1) met the alpha level criterion of <0.20 to be considered for the multivariable predictor analysis for periprocedural stroke. The predictors of early and late stroke are reported in Table 1 . In the multivariable model, besides female sex, the occurrence of acute kidney injury and major vascular complication were identified as significant independent predictors of early stroke. Prior CABG was the only significant independent predictor of late stroke.
We also did not identify any multivariable predictors of periprocedural stroke/TIA events combined on the basis of our model selection criteria. The predictors of early and late stroke or TIA are reported in Table 2 . In the multivariable model, prior AF and major vascular complication were identified as significant independent predictors of early stroke/TIA.
Prior CABG was also a significant independent predictor of late stroke/TIA. 
DISCUSSION
The CoreValve ADVANCE study, the largest, multicenter, prospective, fully monitored, VARC-reported In the ADVANCE study, the incidence of stroke after (mostly transfemoral) TAVR, even in "realworld" patients, was lower compared to the relatively recently published stroke data from both the PARTNER and CoreValve US Pivotal trials (2-4). In the PARTNER trial, the rate of neurological events in high-risk patients treated transfemorally was 3 times higher after TAVR than after SAVR: 4.6% versus 1.4% The majority of stroke events were classified as ischemic at each time point.
JACC VOL. 66, NO. 3, 2015 Bosmans et al. Values are % (n/N) or mean AE SD (n). *An alpha level of 0.20 was used to select univariable predictors. †Hazard ratios and p values are adjusted for the other covariates in the final model. ‡p value is from Type III tests for comparisons across the categorical groups.
TIA transient ischemic attack; other abbreviations as in Table 1 . Values are % (n/N) or mean AE SD (n). *For the very early time period of days 0 to 1 post-transcatheter aortic valve replacement (TAVR), no predictors of stroke were found. †An alpha level of 0.20 was used to select univariable predictors. ‡Hazard ratios and p values are adjusted for the other covariates in the final model. §The p value is from Type III tests for comparisons across categorical groups.
higher stroke rates through 2 years (11). These discrepancies are not easily explained by differences in patient risk profile given that the logistic EuroSCORE in ADVANCE was similar to the SOURCE XT Registry, although our study included fewer patients implanted via a noniliofemoral access route. The fact that ADVANCE and SOURCE XT were performed exclusively in high-volume TAVR sites excludes the effect of possible "learning-curve" influences, at least for these 2 studies, and standard clinical practice would have been similarly applied. Access route, delivery system size, and valve type as well as the criteria for stroke assessment varied among these studies and may have contributed alone or in combination to the differences in overall event rates.
MECHANISMS OF STROKE AFTER TAVR. Periprocedural stroke, accounting for about 30% of strokes after implantation, has a multifactorial etiology. In our analysis, no specific patient or procedure-related characteristics could be identified as a significant predictor for periprocedural stroke. However, most probably, catheter manipulations of the calcified and diseased aortic valve and aortic arch cause embolization of aortic debris or thrombotic material, resulting in stroke or TIA (12) . Therefore, embolic protection devices currently under evaluation might offer potential benefit in reduction of at least some of TAVRrelated neurological complications.
Remarkably, in ADVANCE, 50% of the strokes that occurred within the first 30 days after TAVR were recognized after the first 2-day periprocedural window. Also in the PARTNER trial TAVR-treated highrisk patients, 6 of the 18 neurologic events (TIA, minor or major stroke) that occurred within the first month presented after the 0-to 2-day window (10).
These observations strongly suggest that other determinants, apart from procedural aspects, are significantly related to final neurological outcome. Belgium. E-mail: johan.bosmans@uza.be.
PERSPECTIVES COMPETENCY IN MEDICAL KNOWLEDGE:
Although TAVR has become a standard management strategy for patients with symptomatic aortic valve stenosis facing a high risk of complications with SAVR, a history of atrial fibrillation or CABG identify patients with a higher risk of stroke during the month after TAVR with a self-expandable valve prosthesis at centers with experience performing $40 TAVR procedures.
TRANSLATIONAL OUTLOOK: Additional study is needed to evaluate the generalizability of these correlations to patients undergoing TAVR at less experienced centers requires, and large registry databases could be employed for this purpose as the technique becomes more widely employed.
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